Literature DB >> 17286449

Diagnostic impact of molecular lineage analysis on paraffin-embedded tissue in hematolymphoid neoplasia reclassified by current WHO criteria.

Leonard Hwan Cheong Tan1, Lily-Lily Chiu, Evelyn Siew Chuan Koay.   

Abstract

BACKGROUND AND
OBJECTIVE: By current WHO criteria, most - though not all - cases of hematolymphoid neoplasm can be diagnosed immunomorphologically, diminishing the role of molecular tests for lymphoid antigen receptor clonality in lymphoma diagnosis. Hence, our objective was to glean immunomorphological and molecular correlates from hematolymphoid neoplasms that had remained unresolvable without diagnostic molecular input.
METHODS: Thirty-five such cases were reviewed histologically and with standard immunoperoxidases. In situ hybridization for Epstein-Barr virus (EBV)-encoded RNAs (EBER) was performed on selected cases. PCR amplification of genes encoding T-cell receptors (TcR) and immunoglobulin heavy chains (IgH) [TR and IGH genes, respectively] was performed on whole tissue in all cases, and on microdissected cells in two cases.
RESULTS: Twenty-five cases (71%) requiring diagnostic molecular genotyping had some form of peripheral T-cell lymphoma (PTCL). Twenty (80%) of these were complicated by a proliferation of B-lineage cells, either within the same tissue ('syntopic') as large B cells (LBC) or Reed-Sternberg (RS)-like cells (17 cases), florid lymphoid hyperplasia (two cases, one also with syntopic LBC) or monotypic plasma cells (one case), or at a separate ('metatopic') site as a B-cell lymphoma (two cases, one of which also had syntopic LBC) or Hodgkin lymphoma (HL; one case, also showing syntopic LBC). Fifteen (75%) of these 20 PTCLs with B-lineage proliferation yielded monoclonal TR gene rearrangements, and only two (10%) showed IGH monoclonality, which was transient in one case. Three (18%) of the PTCLs with LBC had originally been misinterpreted as some form of HL. Conversely, of the remaining cases, three of four (75%) that had been diagnosed initially as some form of large cell non-HL (NHL), including two of three that were called 'anaplastic', had to be revised to grade II/syncytial nodular sclerosing (NS) HL, yielding polyclonal TcRgamma gene (TRG) rearrangements, with one case, in addition, disclosing a biallelic clonal IGH gene rearrangement that excluded anaplastic large cell lymphoma. DISCUSSION/
CONCLUSION: Paradoxically, monoclonality of TR rather than IGH gene rearrangement may more often be detectable in a predominantly dispersed ('hodgkinoid'), large B-lineage cell proliferation, consistent with release from immune regulation in the milieu of impaired immunosurveillance within a PTCL. This is compounded by the difficulty in ascertaining clonal IGH gene rearrangements resulting from (1) poor consensus primer hybridization due to somatic hypermutations, and (2) 'dilution' in a T-cell-rich milieu. These same difficulties also account for the long-elusive identification of the RS cell lineage. Conversely, anaplastic lymphoma, which is of non-B lineage, may be mimicked by NSHL, which is of B lineage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17286449     DOI: 10.1007/BF03256221

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  85 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Effective Immunochemotherapy For Aggressive Non-Hodgkin's Lymphoma.

Authors:  Bertrand Coiffier
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

3.  Lymph node architecture in Hodgkin's disease: evidence for the role of the composite nodule in nodular sclerosing Hodgkin's disease.

Authors:  G Van Parys; C De Wolf-Peeters; J J van den Oord; V J Desmet
Journal:  Hematol Oncol       Date:  1987 Apr-Jun       Impact factor: 5.271

Review 4.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Angioimmunoblastic T-cell lymphoma (angioimmunoblastic lymphadenopathy with dysproteinemia [AILD]-type T-cell lymphoma) followed by Hodgkin's disease associated with Epstein-Barr virus.

Authors:  S Nakamura; Y Sasajima; T Koshikawa; K Kitoh; K Koike; T Motoori; R Ueda; S Mori; T Suchi
Journal:  Pathol Int       Date:  1995-12       Impact factor: 2.534

6.  Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: a clinicopathological and immunohistochemical study of 10 cases.

Authors:  M Kojima; S Nakamura; H Itoh; T Motoori; S Sugihara; H Shinkai; N Masawa
Journal:  APMIS       Date:  2001-10       Impact factor: 3.205

7.  Angioimmunoblastic lymphadenopathy type of T-cell lymphoma and angioimmunoblastic lymphadenopathy: a clinicopathological and molecular biological study of 13 Chinese patients using polymerase chain reaction and paraffin-embedded tissues.

Authors:  J Lorenzen; G Li; M Zhao-Höhn; C Wintzer; R Fischer; M L Hansmann
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?

Authors:  C Lome-Maldonado; D Canioni; O Hermine; E Delabesse; D Damotte; E Raffoux; P Gaulard; E Macintyre; N Brousse
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

Review 9.  Immune escape mechanisms in Hodgkin's disease.

Authors:  S Poppema; M Potters; L Visser; A M van den Berg
Journal:  Ann Oncol       Date:  1998       Impact factor: 32.976

10.  Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.

Authors:  Lluís Colomo; Florence Loong; Susana Rives; Stefania Pittaluga; Antonio Martínez; Armando López-Guillermo; Jesús Ojanguren; Vicens Romagosa; Elaine S Jaffe; Elías Campo
Journal:  Am J Surg Pathol       Date:  2004-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.